13224
clinical study

Directing Care with Point of Care Artificial Intelligence: Clinical Impact of Establishing Purposeful Outpatient AI-Directed Management of Incidental Pulmonary Emboli

Materials & Methods

An AI software was introduced in July 2023 at outpatient imaging centers to flag incidental pulmonary embolism (iPE). From July 2023 to March 2024, 11,700 outpatient CT chest and abdomen scans were analyzed. When AI flags a suspected positive case, the radiology technician informs the ARNP, and the patient is moved to a nursing waiting area. The ARNP then consults the radiology clinical coordinator, who confirms the finding with the attending radiologist. If confirmed, the clinical coordinator instructs the ARNP to transfer the patient to the emergency department (ED).

Results

The AI software flagged 80 confirmed iPEs, with an average patient age of 62.7 years (60% male, 94% with cancer history). AI-flagged cases had a median turnaround of 66.4 minutes, an 82.7% (317.2 minute) reduction compared to negatives (P<0.05). Segmental iPEs comprised 35%, and 29% of patients were sent to the ED, where 78% were hospitalized (avg. stay: 4.4 days) and 83% received anticoagulation. One patient underwent thrombectomy, and the Pulmonary Embolism Response Team (PERT) was activated in four cases.

Conclusions

This study demonstrates that an AI-guided triage system can significantly reduce turnaround time for iPE detection, enabling faster ED referrals and timely treatment. AI integration improves patient care, optimizes resource use and warrants further research to assess long-term outcomes.

Disclaimer: This links to a third-party website, which may require credentials to review.

Explore the Latest AI Insights, Trends and Research

Daniel Spector

<p>Daniel Spector is an AI Transformation Consultant at Aidoc. His focus is enabling clinicians and hospital administrators to provide better, more efficient care through the power of AI augmentation for enterprise imaging.</p>

Amalia Schreier

<p>Amalia Schreier serves as the Senior Vice President of Regulatory Affairs and Legal at Aidoc, guiding our company and product’s regulatory strategies and ensuring alignment with AI-focused medical device compliance requirements. Since her tenure began, she has streamlined our FDA clearance processes, emphasizing a meticulous approach that underscores our commitment to product and clinical quality.</p> <p>With a solid foundation from her legal background and leadership role in AI startup regulatory departments, Schreier brings invaluable insights and expertise to our regulatory framework. Prior to her tech world experience, she worked as a human-rights lawyer and legal policy scholar, with a BA and LLM in law from the Hebrew University of Jerusalem.</p>

Deepak Srikant

<p>Deepak Srikant is a global marketing executive with over 20 years of experience, specializing in the commercialization of medical devices and digital health solutions. He has a proven track record in driving growth, having led successful go-to-market strategies, product launches and market expansions across the U.S. and EMEA.</p> <p>Srikant’s expertise extends to upstream and downstream marketing, professional education and sales enablement. His leadership at companies such as Silk Road Medical (acquired by Boston Scientific) and Aptus Endosystems (acquired by Medtronic) has consistently resulted in revenue growth, enhanced customer retention and successful product adoption.</p> <p>Srikant holds an MBA from the Yale School of Management and a bachelor’s degree in mechanical engineering from Rensselaer Polytechnic Institute. Currently, he leads product marketing for Aidoc’s cardiovascular service line.</p>